BioSpace News Archive

Next Generation ALK Inhibitor Candidate, TPX-0131, Overcomes ALK Resistant Mutations in Preclinical Models

Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer , Chief Executive Officer, will participate in a virtual fireside chat at the H.C. Wainwright Virtual Fireside Chat Series on Thursday, June 25, at 10:50 a.m. E.T. The presentation will be webcast and may be accessed through the “Events & Presentations” page on

MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced presentations at the American Association for Cancer Research (AACR) Virtual Annual Meeting II , taking place June 22-24, 2020. “We are pleased to present data at this year’s AACR that highlight three platform technologies upon which

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced new features of mymobility with Apple Watch, creating a first-of-its-kind remote care management system.

Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it will host a webcast and conference call to discuss top-line results from the Phase 3 SPIRIT 1 study of once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with pain associated with endometriosis.

SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the limited commercial launches and completion of initial surgeries of both its NorthStar OCT and Cervical Facet Fusion systems, which significantly expand its procedural offerings for posterior cervical fusion.

Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today the closing of the previously announced public offering of 7,590,000 shares of common stock, including 990,000 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $14.50 per share

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today provided a business update and announced its financial and operating results for the fourth quarter and fiscal year ended March 31, 2020.

Akorn, Inc., a leading specialty generic pharmaceutical company, announced the launch of its Abbreviated New Animal Drug Application for Neomycin and Polymyxin B Sulfates, and Bacitracin Zinc Ophthalmic Ointment, USP.

IVERIC bio, Inc. (Nasdaq: ISEE) (the “Company”), today announced the closing of its underwritten public offering of 28,503,220 shares of its common stock at a price to the public of $4.100 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 1,914,280 shares of its common stock at a price to the public of $4.099 per pre-funded warrant,